Ett nytt kapillärt egenprovtagnings-kit för dosbestämning av läkemedel i blod

 .tb-container .tb-container-inner{width:100%;margin:0 auto} .wp-block-toolset-blocks-container.tb-container[data-toolset-blocks-container="e61a64d295706b5905bc3be92ed86e4b"] { border-radius: 8px;background: rgba( 243, 242, 242, 1 );padding: 48px; } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="83e4f9368be67e17ef7cf73b12562c1d"] { grid-template-columns: minmax(0, 0.735fr) minmax(0, 0.265fr);grid-column-gap: 76px;grid-row-gap: 0px;grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="83e4f9368be67e17ef7cf73b12562c1d"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="83e4f9368be67e17ef7cf73b12562c1d"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="9b97cf110b220d9fa39ed332dd9a6f8c"] { margin-left: 4px;display: flex; } .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="9b97cf110b220d9fa39ed332dd9a6f8c"] p { line-height: 3px; } .tb-field[data-toolset-blocks-field="dfa6bb20d23ade5d44128037c2087b7d"] { font-size: 13px;font-family: Roboto;font-weight: regular;line-height: 16px; }  .tb-field[data-toolset-blocks-field="31537f64838810a0b8f9030d23a1eebd"] { font-size: 13px;font-family: Roboto;font-weight: regular;line-height: 16px;padding-bottom: 6px; }  .tb-field[data-toolset-blocks-field="1486cee24b651bcac937c79e6155c9bf"] { font-size: 13px;font-family: Roboto;font-weight: regular;line-height: 16px;padding-bottom: 6px; }  .tb-field[data-toolset-blocks-field="24bd4910ab3d07fdd44f628d9947393a"] { font-size: 13px;font-family: Roboto;font-weight: regular;line-height: 16px;padding-bottom: 6px; }  .tb-field[data-toolset-blocks-field="031c5e5a15849a827dcb09445b9564dd"] { font-size: 13px;font-family: Roboto;font-weight: regular;line-height: 16px;padding-bottom: 6px; }  .tb-field[data-toolset-blocks-field="4b115832581cb6288c620bbff21fb844"] { font-size: 13px;font-family: Roboto;font-weight: regular;line-height: 16px;padding-top: 0px;padding-bottom: 6px;margin-top: 0px; }  .tb-field[data-toolset-blocks-field="29d76ce207d419a012efb65b8acefd03"] { font-size: 13px;font-family: Roboto;font-weight: regular;line-height: 16px;padding-top: 0px;padding-bottom: 6px;margin-top: 0px; }  h4.tb-heading[data-toolset-blocks-heading="aad2c857f9e298945c7ae5d9c5c8c480"]  { font-size: 22px;font-family: Roboto;font-weight: 300;line-height: 24px; }  .tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em} .tb-button[data-toolset-blocks-button="c96b78e58d378dbd8572eea39aeff915"] { text-align: left; } .tb-button[data-toolset-blocks-button="c96b78e58d378dbd8572eea39aeff915"] .tb-button__link { background-color: rgba( 139, 183, 8, 1 );margin-top: 12px;margin-bottom: 24px;font-size: 14px;font-family: Roboto;font-weight: regular; } .tb-field[data-toolset-blocks-field="199679b582a458bcd9da749881546784"] { font-size: 14px;font-family: Roboto;font-weight: regular;line-height: 18px;color: rgba( 47, 59, 64, 1 ); }  .tb-field[data-toolset-blocks-field="32489777632b4dbb178ccac5bcec8fc9"] { font-size: 14px;font-family: Roboto;font-weight: regular;line-height: 18px;color: rgba( 47, 59, 64, 1 ); }  .tb-field[data-toolset-blocks-field="9dab8c396297b53312f204b873cdf568"] { font-size: 22px;font-family: Roboto;font-weight: 300;line-height: 24px; }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; } .tb-field[data-toolset-blocks-field="a75a43dc56a7b3852ec5dea68af8c8f5"] { font-size: 16px;font-family: Roboto;font-weight: 700;line-height: 18px;text-transform: uppercase;text-align: initial;color: rgba( 139, 183, 8, 1 ); }  .tb-field[data-toolset-blocks-field="4ed92c8c217915fc11adfd6dd309d904"] { font-size: 36px;font-family: Roboto;font-weight: regular;line-height: 38px;text-align: left;color: rgba( 0, 113, 137, 1 ); }  @media only screen and (max-width: 781px) {  .tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="83e4f9368be67e17ef7cf73b12562c1d"] { grid-template-columns: minmax(0, 0.5fr) minmax(0, 0.5fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="83e4f9368be67e17ef7cf73b12562c1d"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="83e4f9368be67e17ef7cf73b12562c1d"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="9b97cf110b220d9fa39ed332dd9a6f8c"] { display: flex; }         .tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em}   .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }    } @media only screen and (max-width: 599px) {  .tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="83e4f9368be67e17ef7cf73b12562c1d"] { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="83e4f9368be67e17ef7cf73b12562c1d"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 } .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="9b97cf110b220d9fa39ed332dd9a6f8c"] { display: flex; }         .tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em}   .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }    } 

ADDUCT ANALYS AB / Redhot diagnostics

Blodprovskit Rhelise™ avsett att användas för lekmän att samla kapillärt helblod för analys av biomarkörer och läkemedelsmetaboliter.

Syftet är att visa att vården kan förbättras genom att tidigt upptäcka patienter som är underdoserade och att pröva att sänka dosen tamoxifen ifall biverkningarna är svåra och den verksamma dosen är hög.

Det är 9 000 kvinnor/år som får diagnosen bröstcancer i Sverige och varje år så är det 40 000 som är ordinerade tamoxifen. Cirka 50% av dessa kvinnor fullföljer inte behandlingen bland annat på grund av svåra biverkningar. Det finns idag inga möjligheter för sjukvården att följa upp de
här kvinnorna. Rhelise kittet är ett snabbt och enkelt sätt att ta ett blodprov och kunna få svar på att den aktiva dosen är tillräcklig. Behandlande läkare kan baserat på resultatet och i samråd med patienten förändra dosen så att en optimal behandling erhålls. Rhelise ger därmed patienten en ökad trygghet.

Läs mer

PROJEKTFAKTA

KATEGORI:

Produkter för egenvård

KOORDINATOR:

ADDUCT ANALYS AB / Redhot diagnostics

PROJEKTNUMMER:

2018-03882

BIDRAG:

1 390 000 kr

STARTDATUM:

januari 20, 2019

SLUTDATUM:

juni 1, 2021

PROJEKTSTATUS:

Avslutade

NY SÖKNING